Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

Adrenal Tumors Clinical Trial

Official title: Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

Status Completed

Clinical Trial Summary

The purpose of this study is to find out if your adrenal glands are normal or abnormal. This can be determined by whether or not your adrenal gland concentrates more of a labeled building block of adrenal hormone, norcholesterol. This labeled material had been used as an investigative diagnostic tool for imaging adrenal glands for many years with success in our hands. This is a diagnostic procedure. CT, MRI and Ultrasound can determine the size and presence or absence of tumor but cannot assess the function of the adrenal glands. To determine hormone concentrations from blood samples would involve more invasive catherization.

Clinical Trial Description

To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Abnormal Hormonal Secretions
• Adrenal Gland Neoplasms
• Adrenal Malignancies
• Adrenal Tumors
• Congenital Abnormalities
• Electrolytes Abnormalities

• NCT number: NCT00591643
• Study type: Interventional
• Source: Memorial Sloan Kettering Cancer Center
• Status: Completed
• Phase: Phase 1
• Start date: July 1977
• Completion date: March 2011